Hepion director buys 2M shares and 2M warrants

Hepion Pharmaceuticals director Michael J. Purcell reported significant insider purchases.

Rhea-AI Filing Summary

Hepion Pharmaceuticals director Michael J. Purcell reported significant insider purchases. On 2026-08-03, he bought 2,000,000 shares of common stock at $0.05 per share, increasing his direct common stock holdings to 3,250,000 shares. He also purchased 2,000,000 warrants with an exercise price of $0.06 per share, exercisable into 2,000,000 common shares and expiring on 2031-08-03, leaving him holding 2,000,000 warrants after the transaction.

Insider Trade Summary

Net Buyer: 4,000,000 shares

Net Buy 2 txns

Insider Purcell Michael J.

Role Director

Bought 4,000,000 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Warrants	2,000,000	$0.00	$0.00
Purchase	Common Stock	2,000,000	$0.05	$100K

Holdings After Transaction: Warrants — 2,000,000 contracts (Direct); Common Stock — 3,250,000 shares (Direct)

Key Figures

Common shares purchased: 2,000,000 shares Purchase price per common share: $0.05 Common shares held after transaction: 3,250,000 shares +3 more

6 metrics

Common shares purchased 2,000,000 shares Common stock bought on 2026-08-03 at $0.05 per share

Purchase price per common share $0.05 Price for 2,000,000 common shares acquired on 2026-08-03

Common shares held after transaction 3,250,000 shares Direct Hepion common stock position after the 2026-08-03 purchase

Warrants purchased 2,000,000 warrants Derivative securities acquired on 2026-08-03

Warrant exercise price $0.06 per share Conversion or exercise price for 2,000,000 warrants into common stock

Warrant expiration date 2031-08-03 Expiration of 2,000,000 warrants acquired on 2026-08-03

Key Terms

Warrants, Exercise price, Expiration date

3 terms

Warrants financial

"security_title: Warrants with an exercise price of $0.06 per share"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Exercise price financial

"conversion_or_exercise_price: 0.0600 indicates the exercise price of the warrants"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Expiration date financial

"expiration_date: 2031-08-03 specifies the warrants' expiration date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did HEPA director Michael J. Purcell report?

Michael J. Purcell reported two purchases on 2026-08-03: 2,000,000 common shares at $0.05 per share and 2,000,000 warrants with a $0.06 exercise price expiring in 2031.

How many Hepion Pharmaceuticals (HEPA) shares does Michael J. Purcell now hold?

After the reported transaction, Michael J. Purcell directly holds 3,250,000 shares of Hepion Pharmaceuticals common stock. This figure reflects his position following the 2,000,000-share purchase on 2026-08-03.

What warrants did the HEPA director acquire in this Form 4 filing?

Michael J. Purcell acquired 2,000,000 warrants on 2026-08-03. Each warrant has an exercise price of $0.06 per share, is exercisable for one share of common stock, and expires on 2031-08-03.

Were the HEPA insider transactions in this Form 4 part of a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed (set to false), meaning these reported purchases are not identified as being made under a Rule 10b5-1 trading plan.

What were the purchase prices in the HEPA Form 4 transactions?

The common stock was purchased at $0.05 per share. The warrants were acquired with an exercise price of $0.06 per share, and the transaction price for the warrants is reported as $0.00 per warrant in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Purcell Michael J.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		2,000,000	A	$0.05	3,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.06	08/03/2026		P		2,000,000		08/03/2026	08/03/2031	Common Stock	2,000,000	$0	2,000,000	D

Explanation of Responses:

	/s/ Michael Purcell	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)